AI-Powered Research

Conditions: Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7
Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7

Interventions: Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Drug: Onalespib
Other: Pharmacological Study

First Posted Date: 2015-03-06

Last Posted Date: 2025-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT02381535

Locations: 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
Yale University, New Haven, Connecticut, United States

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: Nilotinib + Paclitaxel

First Posted Date: 2015-03-05

Last Posted Date: 2025-05-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT02379416

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue

Recruiting

Conditions: Healthy Volunteers
Urinary Tract Cancer
Urothelial Cancer
Bladder Cancer

First Posted Date: 2015-03-05

Last Posted Date: 2025-06-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT02379429

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission

Phase 1

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Berberine Chloride
Other: Laboratory Biomarker Analysis
Other: Placebo Administration

First Posted Date: 2015-02-19

Last Posted Date: 2021-08-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT02365480

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇨🇳
Fourth Military Medical University, Xi'an, Shaanxi, China

Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment

Phase 2

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Peginterferon alfa-2a

First Posted Date: 2015-02-18

Last Posted Date: 2019-09-04

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 14

Registration Number: NCT02364336

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

Phase 2

Completed

Conditions: Recurrent Uveal Melanoma
Stage IV Uveal Melanoma AJCC v7

Interventions: Drug: Glembatumumab Vedotin
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2015-02-16

Last Posted Date: 2020-08-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT02363283

Locations: 🇺🇸
University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
🇺🇸
University of Kansas Clinical Research Center, Fairway, Kansas, United States
🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States

and more 22 locations

Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)

Completed

Conditions: Fatty Liver

First Posted Date: 2015-02-16

Last Posted Date: 2021-08-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 74

Registration Number: NCT02363309

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139

Phase 2

Completed

Conditions: Cancer Of Prostate
Prostate Cancer
Neoplasms of Prostate
Prostatic Neoplasms
Stage D0 Prostate Cancer

Interventions: Biological: Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine

First Posted Date: 2015-02-13

Last Posted Date: 2024-12-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT02362464

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer

Phase 2

Terminated

Conditions: Prostatic Neoplasms
Prostate Cancer

Interventions: Biological: Autologus elutriated monocyte placebo vaccine
Biological: Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine

First Posted Date: 2015-02-13

Last Posted Date: 2022-03-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7

Registration Number: NCT02362451

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Phase 1

Active, not recruiting

Conditions: Recurrent Diffuse Intrinsic Pontine Glioma
Refractory Ependymoma
Lynch Syndrome
Recurrent Brain Neoplasm
Recurrent Childhood Ependymoma
Constitutional Mismatch Repair Deficiency Syndrome
Malignant Glioma
Refractory Diffuse Intrinsic Pontine Glioma
Recurrent Medulloblastoma
Refractory Brain Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Conventional Magnetic Resonance Imaging
Procedure: Diffusion Tensor Imaging
Procedure: Diffusion Weighted Imaging
Procedure: Dynamic Contrast-enhanced MR Perfusion
Procedure: Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging
Procedure: Magnetic Resonance Spectroscopic Imaging
Biological: Pembrolizumab

First Posted Date: 2015-02-10

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 110

Registration Number: NCT02359565

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 9 locations

Home Terms & Conditions Privacy Policy